Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

IF 4.8 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-02-06 DOI:10.1093/oncolo/oyae246

Sandra Castaño-Díez, José Ramón Álamo, Mònica López-Guerra, Marta Gómez-Hernando, Inés Zugasti, Carlos Jiménez-Vicente, Francesca Guijarro, Irene López-Oreja, Daniel Esteban, Paola Charry, Víctor Torrecillas, Lucia Mont-de Torres, Albert Cortés-Bullich, Álex Bataller, Ares Guardia, Daniel Munárriz, Esther Carcelero, Gisela Riu, Ana Triguero, Natalia Tovar, Dolors Vela, Silvia Beà, Dolors Costa, Dolors Colomer, Maria Rozman, Jordi Esteve, Marina Díaz-Beyá

{"title":"Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?","authors":"Sandra Castaño-Díez, José Ramón Álamo, Mònica López-Guerra, Marta Gómez-Hernando, Inés Zugasti, Carlos Jiménez-Vicente, Francesca Guijarro, Irene López-Oreja, Daniel Esteban, Paola Charry, Víctor Torrecillas, Lucia Mont-de Torres, Albert Cortés-Bullich, Álex Bataller, Ares Guardia, Daniel Munárriz, Esther Carcelero, Gisela Riu, Ana Triguero, Natalia Tovar, Dolors Vela, Silvia Beà, Dolors Costa, Dolors Colomer, Maria Rozman, Jordi Esteve, Marina Díaz-Beyá","doi":"10.1093/oncolo/oyae246","DOIUrl":null,"url":null,"abstract":"<p><p>The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884738/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyae246","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

查看原文本刊更多论文

NPM1突变的慢性粒单核细胞白血病还是急性髓系白血病？

2022 年世界卫生组织修订版和 ICC 分类最近修改了慢性粒细胞白血病（CMML）和急性髓性白血病的诊断标准。然而，对于NPM1突变（NPM1mut）的CMML是否应被诊断为急性髓细胞白血病，目前尚无共识。如今，由于其对诊断和治疗的影响，它已成为一个讨论的主题。因此，我们描述了一例被诊断为 CMML NPM1mut 的患者，并简要回顾了相关文献，以强调如何对 NPM1 突变的 CMML 进行分类的不确定性。我们强调全面分子研究的重要性，这对优化患者的个体化治疗至关重要，可使他们获得靶向治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.